Jubilant to Work With Endo Pharmaceuticals on Drug D... ( NOIDA India June 11 /-

Jubilant to Work With Endo Pharmaceuticals on Drug Development

Date:6/11/2009

NOIDA, India, June 11 /PRNewswire/ --

- Collaboration to Provide Endo Pharmaceuticals With New Drug Candidates in Oncology

Jubilant Organosys Ltd., headquartered in Noida, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharmaceutical company. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.

Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization.

Under an initial three-year agreement, Jubilant will receive from Endo research funding and success-based development milestones and royalties on the successful commercialization of the compounds developed.

Endo Pharmaceuticals, is a specialty pharmaceutical company engaged in R&D, sales and marketing of branded and generic medicines in pain management, urology, endocrinology and oncology.

Commenting on the Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: "We are pleased to announce this collaboration with Endo Pharmaceuticals, and look forward to the prospect of contributing to Endo's expanding discovery pipeline. We anticipate significant rewards on successful development of compounds and its subsequent commercialization. This partnership continues to demonstrate Jubilant's mission to be India's largest provider of innovative solutions for accelerating global drug development and enabling affordable patient care."

Dr. Ivan Gergel M.D., Executive Vice President, Research & Development of Endo Pharmaceuticals sai
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening
2. Jubilant and BioLeap Announce New Partnership in Drug Discovery
3. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
4. ADVENTRX Pharmaceuticals Announces Financing
5. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
6. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
7. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
8. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
10. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
11. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation

Post Your Comments:

Jubilant to Work With Endo Pharmaceuticals on Drug D...( NOIDA India June 11 /- - C...)